syros.com (SYRS) Enterprise Value to EBITDA Ratio
Syros Pharmaceuticals operates in an environment of fierce competition with industry behemoths seeking to acquire innovative startups. Production capacities and partner facilities are functioning seamlessly, ensuring the necessary volumes for clinical trials. The market's valuation dynamics for the asset based on the EV/EBITDA multiple currently stands at . Syros Pharmaceuticals relies on partnerships with clinics to develop targeted leukemia drugs using gene expression management methods.
Metric breakdowns and analytics for syros.com (SYRS)
- market price and analyst price targets:
- market capitalization details:
- business book valuation details:
- debt and solvency information:
Total Debt to Capital Syros Pharmaceuticals|SYRS - Long-Term Debt to Capital|Short-Term Debt to Equity Syros Pharmaceuticals, Inc.|SYRS - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Syros Pharmaceuticals, Inc|SYRS - Company Long-Term Liabilities|Company Short-Term Debts Syros Pharmaceuticals|Quick Ratio syros.com
- business earnings and investment ratios data:
SYRS - Net Income|Projected Future Earnings Syros Pharmaceuticals|SYRS - Market Cap to Earnings|Projected Price to Earnings Syros Pharmaceuticals|SYRS - PEG Multiple|Enterprise Value to EBITDA Ratio Syros Pharmaceuticals, Inc|SYRS - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Syros Pharmaceuticals|SYRS - Net earnings per share for the last four quarters|Quarterly EPS earnings growth syros.com|SYRS - Net earnings per share growth this year|Earnings growth forecast for next year Syros Pharmaceuticals
Summary company analysis:SYRS (Syros)
The EV/EBITDA multiple compares the total enterprise value of a business with its operating profit before depreciation, taxes, and interest, thereby excluding the impact of capital structure. By analyzing the EV/EBITDA trend, a professional investor identifies the real value of assets relative to their ability to generate cash flow. For Syros Pharmaceuticals (SYRS), this metric is critical as it reflects the company's valuation against a backdrop of R&D stagnation and a rapid depletion of resources.
Competitors of Syros Pharmaceuticals (SYRS)
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tempus.com TEM|Total Company Value to Operating Income Before Depreciation Ratio Qiagen Corp (QGEN)|IONS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RGEN (repligen.com)|Avidity Biosciences, Inc. (RNA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio CRSP (CRISPR Therapeutics Inc)|WGS (Sema4) - EV/EBITDA Multiple|RARE: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BEAM|EV/EBITDA Multiple sarepta.com (SRPT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience, Inc. TWST|Business Value to Operating Income Before Depreciation TXG|NTLA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Stoke Corp (STOK) - Enterprise Value to EBITDA Ratio|BLFS: EV/EBITDA Multiple|wavelifesciences.com (WVE) - EV/EBITDA Multiple|MAZE (Maze Therapeutics) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Sionna Therapeutics, Inc. (SION)|EV/EBITDA Multiple PRME|TSHA - Company Value to EBITDA|uniQure N.V. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple meiragtx.com MGTX|RGNX: Enterprise Value to EBITDA Ratio|Solid Biosciences Inc - Enterprise Value to Operating Income Before Depreciation Ratio|OCGN: EV/EBITDA Multiple|PACB - Total Company Value to Operating Income Before Depreciation Ratio|BNTC (Benitec Biopharma Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio designtx.com (DSGN)|EV/EBITDA Multiple RCKT|EV/EBITDA Multiple 4DMT (FDMT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexeo Therapeutics, Inc. LXEO|Korro Bio Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|EDIT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio silence-therapeutics.com SLN|proqr.com (PRQR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CDXS - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio SGMO|Company Value to EBITDA Nautilus Biotechnology Inc NAUT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Metagenomi, Inc. (MGX)|DTIL (precisionbiosciences.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Generation Bio GBIO|Total Company Value to Operating Income Before Depreciation Ratio Boundless Bio Inc. (BOLD)|Exicure Corp - EV/EBITDA Multiple|IMNN (Imunon, Inc.) - Enterprise Value to Operating Income Before Depreciation|phiopharma.com (PHIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation MBIO|RNAZ (TransCode Therapeutics Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Bionano|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Applied DNA (APDN)|Total Company Value to Operating Income Before Depreciation Ratio bluebird bio, Inc|ImmunoPrecise Antibodies Ltd. - Enterprise Value to EBITDA Ratio|omegatherapeutics.com (OMGA) - Company Value to EBITDA|OMIC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation RGLS (Regulus Therapeutics, Inc.)|Codex DNA (TBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA TRACON Pharmaceuticals, Inc (TCON)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology
